Drug Profile

SBP 401

Alternative Names: SBP-401

Latest Information Update: 19 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Idiopathic pulmonary fibrosis
New Molecular Entity Yes

18 Aug 2025 Phase-II clinical trials in Idiopathic pulmonary fibrosis in Soth Korea (unspecified route) before August 2025 (Sprak Biopharma Pipeline, August 2025)
31 Aug 2024 Ministry of Food and Drug Safety approves IND application for SBP 401 for phase-II trial in Idiopathic pulmonary fibrosis in South Korea (Spark Biopharma website, January 2025).
29 Feb 2024 SBP 401 receives Orphan Drug status for Idiopathic pulmonary fibrosis in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com